|
1
|
Van Cutsem E, Sagaert X, Topal B,
Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen CN, Lin JJ, Chen JJ, Lee PH, Yang CY,
Kuo ML, Chang KJ and Hsieh FJ: Gene expression profile predicts
patient survival of gastric cancer after surgical resection. J
Clin. Oncol. 23:7286–7295. 2005.
|
|
3
|
Jiang C, Chen X, Alattar M, Wei J and Liu
H: MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis
of gastric cancer. Cancer Gene Ther. 22:291–301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan
Y, Zhou J and Li G: Overexpression of Cullin1 is associated with
poor prognosis of patients with gastric cancer. Hum Pathol.
42:375–383. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang S, Wu X, Zhang J, Chen Y, Xu J, Xia
X, He S, Qiang F, Li A, Shu Y, et al: CHIP functions as a novel
suppressor of tumour angiogenesis with prognostic significance in
human gastric cancer. Gut. 62:496–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deng J, Liang H, Ying G, Zhang R, Wang B,
Yu J, Fan D and Hao X: Methylation of CpG sites in RNF180 DNA
promoter prediction poor survival of gastric cancer. Oncotarget.
5:3173–3183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
National Comprehensive Cancer Network
(NCCN), . NCCN clinical practice guidelines in oncology (NCCN
guidelines). Gastric cancer. 2016.http://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp
|
|
8
|
Bhide SA and Nutting CM: Recent advances
in radiotherapy. BMC Med. 8:252010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dahele M, Skinner M, Schultz B, Cardoso M,
Bell C and Ung YC: Adjuvant radiotherapy for gastric cancer: A
dosimetric comparison of 3-dimensional conformal radiotherapy,
tomotherapy and conventional intensity modulated radiotherapy
treatment plans. Med Dosim. 35:115–121. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kurokawa M, Kim J, Geradts J, Matsuura K,
Liu L, Ran X, Xia W, Ribar TJ, Henao R, Dewhirst MW, et al: A
network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1
control apoptosis independently of p53. Sci Signal. 6:ra322013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sane S and Rezvani K: Essential roles of
E3 ubiquitin ligases in p53 regulation. Int J Mol Sci. 18(pii):
E4422017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reymond A, Meroni G, Fantozzi A, Merla G,
Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, et
al: The tripartite motif family identifies cell compartments. EMBO
J. 20:2140–2151. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gushchina LV, Kwiatkowski TA, Bhattacharya
S and Weisleder NL: Conserved structural and functional aspects of
the tripartite motif gene family point towards therapeutic
applications in multiple diseases. Pharmacol Ther. 185:12–25. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sereno M, De Castro J, Cejas P,
Garcia-Cabezas MA, Belda C, Casado E, Feliu J, Gómez C, López M and
Barón MG: Expression profile as predictor of relapse after adjuvant
treatment in gastric cancer. J Gastrointest Cancer. 43:181–189.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hamada M, Fujiwara T, Hizuta A, Gochi A,
Naomoto Y, Takakura N, Takahashi K, Roth JA, Tanaka N and Orita K:
The p53 gene is a potent determinant of chemosensitivity and
radiosensitivity in gastric and colorectal cancers. J Cancer Res
Clin Oncol. 122:360–365. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dai Y and Grant S: New insights into
checkpoint kinase 1 in the DNA damage response signaling network.
Clin Cancer Res. 16:376–383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fei P and El-Deiry WS: P53 and radiation
responses. Oncogene. 22:5774–5783. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou BB and Elledge SJ: The DNA damage
response: Putting checkpoints in perspective. Nature. 408:433–439.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Picksley SM and Lane DP: The p53-mdm2
autoregulatory feedback loop: A paradigm for the regulation of
growth control by p53? Bioessays. 15:689–690. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jang BS and Kim IA: A radiosensitivity
gene signature and PD-L1 status predict clinical outcome of
patients with invasive breast carcinoma in the cancer genome atlas
(TCGA) dataset. Radiother Oncol. 124:403–410. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun YQ, Xie JW, Xie HT, Chen PC, Zhang XL,
Zheng CH, Li P, Wang JB, Lin JX, Cao LL, et al: Expression of CRM1
and CDK5 shows high prognostic accuracy for gastric cancer. World J
Gastroenterol. 23:2012–2022. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kashimoto K, Komatsu S, Ichikawa D, Arita
T, Konishi H, Nagata H, Takeshita H, Nishimura Y, Hirajima S,
Kawaguchi T, et al: Overexpression of TRIM44 contributes to
malignant outcome in gastric carcinoma. Cancer Sci. 103:2021–2026.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirst DG and Robson T: Molecular biology:
The key to personalised treatment in radiation oncology? Br J
Radiol. 83:723–728. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sobin LH, Gospodarowicz MK and Wittekind:
UICC TNM. Classification of malignant tumours. (7th). Wiley &
Liss. (New York). 2009.
|
|
25
|
Deshaies RJ and Joazeiro CA: RING domain
E3 ubiquitin ligases. Annu Rev Biochem. 78:399–434. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Aravind L and Koonin EV: The U box is a
modified RING finger - a common domain in ubiquitination. Curr
Biol. 10:R132–R134. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rohde JR, Breitkreutz A, Chenal A,
Sansonetti PJ and Parsot C: Type III secretion effectors of the
IpaH family are E3 ubiquitin ligases. Cell Host Microbe. 1:77–83.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qiu J, Sheedlo MJ, Yu K, Tan Y, Nakayasu
ES, Das C, Liu X and Luo ZQ: Ubiquitination independent of E1 and
E2 enzymes by bacterial effectors. Nature. 533:120–124. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hou YC and Deng JY: Role of E3 ubiquitin
ligases in gastric cancer. World J Gastroenterol. 21:786–793. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Milne AN, Leguit R, Corver WE, Morsink FH,
Polak M, de Leng WW, Carvalho R and Offerhaus GJ: Loss of
CDC4/FBXW7 in gastric carcinoma. Cell Oncol. 32:347–359.
2010.PubMed/NCBI
|
|
31
|
Calcagno DQ, Freitas VM, Leal MF, de Souza
CR, Demachki S, Montenegro R, Assumpção PP, Khayat AS, Smith Mde A,
dos Santos AK and Burbano RR: MYC, FBXW7 and TP53 copy number
variation and expression in gastric cancer. BMC Gastroenterol.
13:1412013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Burdelya LG, Komarova EA, Hill JE, Browder
T, Tararova ND, Mavrakis L, DiCorleto PE, Folkman J and Gudkov AV:
Inhibition of p53 response in tumor stroma improves efficacy of
anticancer treatment by increasing antiangiogenic effects of
chemotherapy and radiotherapy in mice. Cancer Res. 66:9356–9361.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lewanski CR and Gullick WJ: Radiotherapy
and cellular signalling. Lancet Oncol. 2:366–370. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Caratozzolo MF, Micale L, Turturo MG,
Cornacchia S, Fusco C, Marzano F, Augello B, D'Erchia AM, Guerrini
L, Pesole G, et al: TRIM8 modulates p53 activity to dictate cell
cycle arrest. Cell Cycle. 11:511–523. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hock AK and Vousden KH: The role of
ubiquitin modification in the regulation of p53. Biochim Biophys
Acta. 1843:137–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu F, Yang X, Geng M and Huang M:
Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer
therapy. Acta Pharm Sin B. 8:552–562. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Martins-Neves SR, Cleton-Jansen AM and
Gomes CMF: Therapy-induced enrichment of cancer stem-like cells in
solid human tumors: Where do we stand? Pharmacol Res. 137:193–204.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Song Q, Jiang S, Zhang X, Pan C, Lu C,
Peng J and Li Q: Radiosensitivity of human ovarian cancer cells is
enhanced by pseudolaric acid B due to the inhibition of the
Ras/Raf/ERK signaling pathway. Exp Ther Med. 15:685–690.
2018.PubMed/NCBI
|
|
39
|
Liang C, Wang S, Qin C, Bao M, Cheng G,
Liu B, Shao P, Lv Q, Song N, Hua L, et al: TRIM36, a novel
androgen-responsive gene, enhances anti-androgen efficacy against
prostate cancer by inhibiting MAPK/ERK signaling pathways. Cell
Death Dis. 9:1552018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sharabi AB, Lim M, DeWeese TL and Drake
CG: Radiation and checkpoint blockade immunotherapy:
Radiosensitisation and potential mechanisms of synergy. Lancet
Oncol. 16:e498–e509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Twyman-Saint Victor C, Rech AJ, Maity A,
Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi
PM, et al: Radiation and dual checkpoint blockade activate
non-redundant immune mechanisms in cancer. Nature. 520:373–377.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhu Z, Wang Y, Zhang C, Yu S, Zhu Q, Hou K
and Yan B: TRIM25 blockade by RNA interference inhibited migration
and invasion of gastric cancer cells through TGF-β signaling. Sci
Rep. 6:190702016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhou Z, Ji Z, Wang Y, Li J, Cao H, Zhu HH
and Gao WQ: TRIM59 is up-regulated in gastric tumors, promoting
ubiquitination and degradation of p53. Gastroenterology.
147:1043–1054. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Balint I, Müller A, Nagy A and Kovacs G:
Cloning and characterisation of the RBCC728/TRIM36 zinc-binding
protein from the tumor suppressor gene region at chromosome 5q22.3.
Gene. 332:45–50. 2004. View Article : Google Scholar : PubMed/NCBI
|
